Amgen (AMGN) has several important developments on the horizon. It is expected that Amgen's earnings will grow, with anticipation building ahead of the release of the company's Q3 financial results. An interesting development of note is the failure of Regeneron to block the launch of Amgen's biosimilar of Eylea in the US. Another is the approval of Amgen's Blincyto for consolidation treatment by the FDA.
With respect to the AMGN stock, investors are keen to see if it can reach record levels by the end of 2024. However, its stock has seen decreases more significantly than the broader market on some days but also has seen increases on other days. Analysts' ratings have also shown mixed signals.
Amgen's obesity drug represents a potential $5 billion dollar opportunity but has led to a stock downgrade. Despite this, data on its obesity drug, MariTide, has led to increased confidence and stock jumps. Development of Amgen's muscular disorder drug has met its main objective in a late-stage study. Its Rocatinlimab drug, despite the competitive landscape, has been identified as having commercial potential.
Amgen AMGN News Analytics from Wed, 03 Apr 2024 07:00:00 GMT to Sat, 26 Oct 2024 13:24:44 GMT - Rating 4 - Innovation 5 - Information 6 - Rumor -2
